Back to top
more

Savara (SVRA)

(Delayed Data from NSDQ)

$4.24 USD

4.24
1,002,259

-0.45 (-9.59%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $4.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks

Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Top Breakout Stocks to Add to Your Portfolio Now

Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Implied Volatility Surging for Savara (SVRA) Stock Options

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Savara (SVRA) Stock We Don't?

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Savara (SVRA) Stock?

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Savara to Stop Study on Molgradex for NTM Lung Infection

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

Savara Enters Oversold Territory

Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Savara Sees Hammer Chart Pattern: Time to Buy?

Savara has been struggling lately, but the selling pressure may be coming to an end soon.

Is a Surprise Coming for Savara (SVRA) This Earnings Season?

Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Company News For Oct 3, 2019

Companies in the news are: SVRA, LEN, F, JNJ

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Savara Plunges on Failure of Late-Stage Study on Molgradex

Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

Implied Volatility Surging for Savara (SVRA) Stock Options

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Savara Inc (SVRA) Upgraded to Buy: Here's Why

Savara Inc (SVRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Savara Inc (SVRA) Upgraded to Buy: Here's Why

Savara Inc (SVRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).